Seili Medical increases capital for Wuhan Huajiyuan Bio to support the development of hypertensive vaccines
Recently, Selli Medical announced a strategic capital increase to Wuhan Huajiyuan Bio to support its research and development project for hypertension vaccines. This cooperation has attracted widespread attention from the industry and has become one of the hotly discussed areas of medical and health care that have been hotly discussed across the Internet in the past 10 days. This article will combine structured data to analyze the significance of this cooperation and the current progress in the development of hypertensive vaccines.
1. Cooperation background and core data
The amount of funds and shareholding ratio of Selli Medical this time are shown in the following table:
| Investor | Invested in the company | Increased funds (billion yuan) | Shareholding ratio |
|---|---|---|---|
| Selli Medical | Wuhan Huajiyuan Biology | 1.5 | 22.5% |
Wuhan Huajiyuan Biological was founded in 2018 and focuses on the research and development of innovative therapies for cardiovascular diseases. Its hypertension vaccine project has entered the preclinical research stage. The following table shows the key time nodes of the project:
| R&D stage | Estimated completion time | Main objectives |
|---|---|---|
| Preclinical research | 2024Q2 | Complete animal experiments |
| Phase I clinical | 2025Q1 | Security Verification |
| Phase II clinical | 2026Q3 | Validity Assessment |
2. Analysis of the market potential of hypertensive vaccines
According to data from the National Center for Cardiovascular Disease, the number of hypertensive patients in my country continues to rise, and the market has an urgent need for innovative therapies:
| years | Number of patients (billions) | Treatment rate | Control rate |
|---|---|---|---|
| 2020 | 2.45 | 45.8% | 16.8% |
| 2023 | 2.7 | 48.3% | 18.2% |
Industry experts pointed out that compared with traditional antihypertensive drugs, hypertensive vaccines have significant advantages:
| Contrast dimensions | Traditional medicine | Vaccine Therapy |
|---|---|---|
| Frequency of medication | Take it daily | Half a year/time |
| Compliance | About 60% | Estimated 85%+ |
| side effect | More common | Probably lower |
3. Capital market reaction and industry impact
After the news was announced, the stock prices of relevant companies were as follows:
| Company Name | 3-day increase | Changes in trading volume |
|---|---|---|
| Selli Medical | +12.6% | Increased 280% |
| Biomedical sector | +3.2% | Grow 45% |
It is worth noting that this is the first hypertensive vaccine project in China to receive strategic investment from listed companies. Analysts believe that this move will accelerate the development process of domestic cardiovascular innovative drugs. The following table lists the recent progress of similar R&D projects:
| enterprise | R&D stage | Technical route |
|---|---|---|
| Huajiyuan Biology | Preclinical | DNA vaccine |
| International Pharmaceutical Company A | Phase II clinical | Antibody vaccine |
| Research Institution B | Basic research | RNA vaccine |
4. Expert views and future prospects
Many industry experts expressed optimism about this cooperation. Professor Wang of the Chinese Academy of Medical Sciences pointed out: "The research and development of hypertensive vaccines requires long-term investment, and strategic cooperation among enterprises can effectively share risks." The CEO of Wuhan Huajiyuan revealed that the new funds will be mainly used for:
| use | Fund share |
|---|---|
| Preclinical research | 40% |
| Talent introduction | 30% |
| Equipment upgrade | 20% |
| other | 10% |
Seli Medical said that it will consider additional investment in the future based on the progress of R&D and plans to establish a joint laboratory. The industry predicts that if the R&D goes smoothly, the vaccine is expected to be approved for market launch around 2028, and the potential market size can reach 10 billion yuan.
This cooperation not only brings new hope for patients with hypertension, but also marks an important step in the field of cardiovascular innovative drugs. As population aging intensifies, the market value of preventive medical products will become increasingly prominent.
check the details
check the details
en
